Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06443463 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-term Safety and Tolerability of BHV-7000

StatusEnrolling by Invitation
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 284 to 283v42
  2. Study sites: 283 to 284v41
  3. Study sites revised (283)v40
  4. Study sites: 281 to 283v39
  5. Study sites: 279 to 281v38
Show 36 earlier versionsHide 36 earlier versions
  1. Study sites: 265 to 279v37
  2. Study sites: 257 to 265v36
  3. Study sites: 242 to 257v35
  4. Study sites: 231 to 242v34
  5. Study sites: 230 to 231v33
  6. Study sites: 229 to 230v32
  7. Study sites: 228 to 229v31
  8. Study sites: 227 to 228v30
  9. Study sites: 226 to 227v29
  10. Study sites: 224 to 226v28
  11. Study sites: 221 to 224v27
  12. Study sites: 220 to 221v26
  13. Study sites: 219 to 220v25
  14. Study sites: 218 to 219v24
  15. Study sites: 210 to 218v23
  16. Study sites: 207 to 210v22
  17. Study sites: 206 to 207v21
  18. Study sites: 205 to 206v20
  19. Study sites: 204 to 205v19
  20. Study sites: 202 to 204v18
  21. Study sites: 203 to 202v17
  22. Study sites: 200 to 203v16
  23. Study sites: 199 to 200v15
  24. Study sites: 198 to 199v14
  25. Study sites: 197 to 198v13
  26. Study sites: 187 to 197v12
  27. Study sites: 174 to 187v11
  28. Study sites: 160 to 174v10
  29. Study sites: 144 to 160v9
  30. Study sites: 129 to 144v8
  31. Study sites: 75 to 129v7
  32. Site details revised at 1 of 75 sitesv6
  33. Start date changed from estimate of Jul 2024 to Jul 30, 2024v5
  34. Re-verified, no change to tracked fieldsv4
  35. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Study sites: 0 to 75
    v3
  36. Primary endpoints: 1 to 2v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy
Trial Details
NCT Number NCT06443463
Lead Sponsor Biohaven Therapeutics Ltd.
Conditions
(from sponsor)		 Focal Epilepsy
Related terms Drug Resistant Epilepsy, Epilepsies, Partial, Epilepsy, Seizures
Enrollment 660 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov